EcoDrugPlus

Ensembl ID : ENSAPOG00000001368
Gene Symbol: -
Cross references: -
209 Possible Orthologues:

Ensembl ID : ENSAPOG00000001365
Gene Symbol: -
Cross references: -
209 Possible Orthologues:

Ensembl ID : ENSAPOG00000017492
Gene Symbol: -
Cross references: -
210 Possible Orthologues:

Ensembl ID : ENSAPOG00000017520
Gene Symbol: -
Cross references: -
211 Possible Orthologues:

Ensembl ID : ENSAPOG00000021348
Gene Symbol: -
Cross references: -
204 Possible Orthologues:

Ensembl ID : ENSAPOG00000021408
Gene Symbol: -
Cross references: -
191 Possible Orthologues:

Ensembl ID : ENSAPOG00000007749
Gene Symbol: -
Cross references: -
233 Possible Orthologues:

Ensembl ID : ENSAPOG00000013091
Gene Symbol: -
Cross references: -
209 Possible Orthologues:

Ensembl ID : ENSAPOG00000022604
Gene Symbol: -
Cross references: -
207 Possible Orthologues:

Ensembl ID : ENSAPOG00000011605
Gene Symbol: -
Cross references: -
221 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).